: The voltage-dependent anion-selective channel isoform 1 (VDAC1) is a pivotal component in cellular metabolism and apoptosis with a prominent role in many cancer types, offering a unique therapeutic intervention point. Through an in-silico-to-in-vitro approach we identified a set of VA molecules (VDAC Antagonists) that selectively bind to VDAC1 and display specificity toward cancer cells. Biochemical characterization showed that VA molecules can directly interact with VDAC1 with micromolar affinity by competing with the endogenous ligand NADH for a partially shared binding site. NADH displacement results in mitochondrial distress and reduced cell proliferation, especially when compared to non-cancerous cells. Experiments performed on organoids derived from intrahepatic cholangiocarcinoma patients demonstrated a dose-dependent reduction in cell viability upon treatment with VA molecules with lower impact on healthy cells than conventional treatments like gemcitabine. VA molecules are chemical entities representing promising candidates for further optimization and development as cancer therapy strategies through precise metabolic interventions.

VDAC1-interacting molecules promote cell death in cancer organoids through mitochondrial-dependent metabolic interference / Conti Nibali, Stefano; De Siervi, Silvia; Luchinat, Enrico; Magrì, Andrea; Messina, Angela; Brocca, Lorenza; Mantovani, Stefania; Oliviero, Barbara; Mondelli, Mario U.; De Pinto, Vito; Turato, Cristian; Arrigoni, Cristina; Lolicato, Marco. - In: ISCIENCE. - ISSN 2589-0042. - ELETTRONICO. - 27:(2024), pp. 109853.0-109853.0. [10.1016/j.isci.2024.109853]

VDAC1-interacting molecules promote cell death in cancer organoids through mitochondrial-dependent metabolic interference

Luchinat, Enrico;
2024

Abstract

: The voltage-dependent anion-selective channel isoform 1 (VDAC1) is a pivotal component in cellular metabolism and apoptosis with a prominent role in many cancer types, offering a unique therapeutic intervention point. Through an in-silico-to-in-vitro approach we identified a set of VA molecules (VDAC Antagonists) that selectively bind to VDAC1 and display specificity toward cancer cells. Biochemical characterization showed that VA molecules can directly interact with VDAC1 with micromolar affinity by competing with the endogenous ligand NADH for a partially shared binding site. NADH displacement results in mitochondrial distress and reduced cell proliferation, especially when compared to non-cancerous cells. Experiments performed on organoids derived from intrahepatic cholangiocarcinoma patients demonstrated a dose-dependent reduction in cell viability upon treatment with VA molecules with lower impact on healthy cells than conventional treatments like gemcitabine. VA molecules are chemical entities representing promising candidates for further optimization and development as cancer therapy strategies through precise metabolic interventions.
2024
27
0
0
Goal 3: Good health and well-being
Conti Nibali, Stefano; De Siervi, Silvia; Luchinat, Enrico; Magrì, Andrea; Messina, Angela; Brocca, Lorenza; Mantovani, Stefania; Oliviero, Barbara; M...espandi
File in questo prodotto:
File Dimensione Formato  
PIIS2589004224010757.pdf

accesso aperto

Descrizione: Versione dell'editore
Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 4.88 MB
Formato Adobe PDF
4.88 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1374533
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact